Serum Cytokeratin 18 Fragment Is an Indicator for Treating Metabolic Dysfunction-Associated Steatotic Liver Disease

Serum Cytokeratin 18 Fragment Is an Indicator for Treating Metabolic Dysfunction-Associated Steatotic Liver Disease

Background and Aims: Although numerous noninvasive diagnostic methods have been developed to predict liver fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD), they lack markers for predicting lobular inflammation, hepatocellular ballooning, or changes related to metabolic d...

Full description

Saved in:
Bibliographic Details
Main Authors: Miwa Kawanaka, Yoshihiro Kamada, Hirokazu Takahashi, Michihiro Iwaki, Ken Nishino, Wenli Zhao, Yuya Seko, Masato Yoneda, Yoshihito Kubotsu, Hideki Fujii, Yoshio Sumida, Hirofumi Kawamoto, Yoshito Itoh, Atsushi Nakajima, Takeshi Okanoue, Takumi Kawaguchi, Masafumi Ono, Hideyuki Hyogo, Yuichiro Eguchi, Takaomi Kessoku, Hiroshi Ishiba
Format: Article
Language:English
Published: Elsevier 2024-01-01
Series:Gastro Hep Advances
Subjects:
Cytokeratin 18 Fragment (CK18F)
MASH Resolution
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
At Risk MASH
MAFLD Fibrosis Score (MAS score)
Online Access:http://www.sciencedirect.com/science/article/pii/S2772572324001225
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2772572324001225

Similar Items